FDA has just approved Ed Lilly's tirzepatide for weight loss.
The new drug will be called Zepbound.
Not good news for RMD at first glance, but the pricing, the
fact that insurance companies are starting to exclude weight
loss drugs from their policies and the growing list of side effects
(overweight rats developed thyroid cancer!) should deter a few.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$40.17 |
Change
0.450(1.13%) |
Mkt cap ! $23.42B | |||
| Open | High | Low | Value | Volume |
| $39.85 | $40.17 | $39.85 | $27.63M | 689.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70 | $40.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $40.18 | 1000 | 1 |
View Market Depth
| Last trade - 16.14pm 22/07/2025 (20 minute delay) ? |
| RMD (ASX) Chart |